Rucaparib’s mechanism of action

Rucaparib (Rucaparib) is an inhibitor of poly(ADP-ribose) polymerase (PARP), including PARP-1, PARP-2 and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucapanib-induced cytotoxicity may involve inhibition of PARP enzyme activity and increased formation of PARP-DNA complexes, leading to DNA damage, apoptosis, and cancer cell death. Increased rucapanib-induced cytotoxicity and antitumor activity were observed in tumor cell lines lacking BRCA 1/2 and other DNA repair genes. Rucaparib has been shown to reduce tumor growth in mouse xenograft models of human cancer with or without BRCA deficiency.